| Title |
Human Papillomavirus Vaccines: Successes and Future Challenges
|
|---|---|
| Published in |
Drugs, September 2018
|
| DOI | 10.1007/s40265-018-0975-6 |
| Pubmed ID | |
| Authors |
Samara Perez, Gregory D. Zimet, Ovidiu Tatar, Nathan W. Stupiansky, William A. Fisher, Zeev Rosberger |
| Abstract |
Over a decade has passed since the first human papillomavirus (HPV) vaccine was introduced. These vaccines have received unequivocal backing from the scientific and medical communities, yet continue to be debated in the media and within the general public. The current review is an updated examination that the authors made five years ago on some of the key sociocultural and behavioral issues associated with HPV vaccine uptake and acceptability, given the changing HPV vaccine policies and beliefs worldwide. We explore current worldwide HPV vaccination rates, outline HPV vaccine policies, and revisit critical issues associated with HPV vaccine uptake including: risk compensation, perceptions of vaccine safety and efficacy, age of vaccination, and healthcare provider (HCP) recommendation and communication. While public scrutiny of the vaccine has not subsided, empirical evidence supporting its safety and efficacy beyond preventing cervical cancer has amassed. There are conclusive findings showing no link that vaccinated individuals engage in riskier sexual behaviors as a result of being immunized (risk compensation) both at the individual and at the policy level. Finally, HCP recommendation continues to be a central factor in HPV vaccine uptake. Studies have illuminated how HCP practices and communication enhance uptake and alleviate misperceptions about HPV vaccination. Strategies such as bundling vaccinations, allowing nurses to vaccinate via "standing orders," and diversifying vaccination settings (e.g., pharmacies) may be effective steps to increase rates. The successes of HPV vaccination outweigh the controversy, but as the incidence of HPV-related cancers rises, it is imperative that future research on HPV vaccine acceptability continues to identify effective and targeted strategies to inform HPV vaccination programs and improve HPV coverage rates worldwide. |
X Demographics
The data shown below were collected from the profiles of 89 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 21 | 24% |
| New Zealand | 3 | 3% |
| United Kingdom | 2 | 2% |
| Denmark | 1 | 1% |
| United States | 1 | 1% |
| Spain | 1 | 1% |
| El Salvador | 1 | 1% |
| Canada | 1 | 1% |
| Unknown | 58 | 65% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 85 | 96% |
| Science communicators (journalists, bloggers, editors) | 3 | 3% |
| Scientists | 1 | 1% |
Mendeley readers
The data shown below were compiled from readership statistics for 109 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 109 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 18 | 17% |
| Student > Bachelor | 11 | 10% |
| Student > Ph. D. Student | 10 | 9% |
| Researcher | 7 | 6% |
| Student > Postgraduate | 7 | 6% |
| Other | 17 | 16% |
| Unknown | 39 | 36% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 26 | 24% |
| Nursing and Health Professions | 13 | 12% |
| Immunology and Microbiology | 6 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 5% |
| Psychology | 3 | 3% |
| Other | 15 | 14% |
| Unknown | 41 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 67. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 March 2020.
All research outputs
#647,045
of 25,746,891 outputs
Outputs from Drugs
#51
of 3,483 outputs
Outputs of similar age
#13,777
of 353,800 outputs
Outputs of similar age from Drugs
#2
of 34 outputs
Altmetric has tracked 25,746,891 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,483 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.1. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 353,800 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 34 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.